MedPath

Aristea Therapeutics, Inc.

Aristea Therapeutics, Inc. logo
🇺🇸United States
Ownership
Holding
Established
2018-01-01
Employees
1
Market Cap
-
Website
http://aristeatx.com

A Study to Evaluate RIST4721 in Familial Mediterranean Fever (FMF)

Phase 2
Withdrawn
Conditions
Familial Mediterranean Fever
Interventions
First Posted Date
2022-07-07
Last Posted Date
2023-02-13
Lead Sponsor
Aristea Therapeutics, Inc.
Registration Number
NCT05448391

A Study to Evaluate RIST4721 in Hidradenitis Suppurativa (HS)

Phase 2
Terminated
Conditions
Hidradenitis Suppurativa
Interventions
Drug: Placebo
First Posted Date
2022-04-27
Last Posted Date
2023-06-13
Lead Sponsor
Aristea Therapeutics, Inc.
Target Recruit Count
25
Registration Number
NCT05348681
Locations
🇺🇸

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

🇺🇸

Florida Academic Centers Research and Education, LLC, Coral Gables, Florida, United States

🇺🇸

USC IDS Pharmacy, Los Angeles, California, United States

and more 9 locations

A Phase 2b Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)

Phase 2
Terminated
Conditions
Palmoplantar Pustulosis
Interventions
Drug: Placebo
First Posted Date
2022-01-18
Last Posted Date
2023-06-29
Lead Sponsor
Aristea Therapeutics, Inc.
Target Recruit Count
79
Registration Number
NCT05194839
Locations
🇺🇸

Clinical Science Institute, Santa Monica, California, United States

🇺🇸

Encore Medical Research, LLC, Hollywood, Florida, United States

🇺🇸

Aventiv Research Inc., Dublin, Ohio, United States

and more 47 locations

A Study of the ADME of [14C]RIST4721 in Healthy Male Subjects

Phase 1
Completed
Conditions
ADME
Healthy
Interventions
First Posted Date
2021-08-27
Last Posted Date
2022-01-10
Lead Sponsor
Aristea Therapeutics, Inc.
Target Recruit Count
6
Registration Number
NCT05023811
Locations
🇬🇧

Quotient Sciences Ltd, Nottingham, United Kingdom

A Study to Investigate the Effects of RIST4721 on the Inflammatory Response in Healthy Male Subjects Using a Blister Model

Phase 1
Completed
Conditions
Inflammatory Response
Interventions
Drug: Placebo
First Posted Date
2019-09-26
Last Posted Date
2020-06-29
Lead Sponsor
Aristea Therapeutics, Inc.
Target Recruit Count
32
Registration Number
NCT04105959
Locations
🇬🇧

MAC Clinical Research, Manchester, United Kingdom

A Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)

Phase 2
Completed
Conditions
Palmoplantar Pustulosis
Interventions
Drug: Placebo
First Posted Date
2019-06-17
Last Posted Date
2022-04-05
Lead Sponsor
Aristea Therapeutics, Inc.
Target Recruit Count
35
Registration Number
NCT03988335
Locations
🇨🇦

Brunswick Dermatology Center, Fredericton, New Brunswick, Canada

🇩🇪

Hautarztpraxis Dr. Niesmann & Dr. Othlinghaus, Bochum, Germany

🇨🇦

Lynderm Research Inc., Markham, Ontario, Canada

and more 14 locations
© Copyright 2025. All Rights Reserved by MedPath